PLoS ONE (Jan 2014)

Smoking is a risk factor for the progression of idiopathic membranous nephropathy.

  • Makoto Yamaguchi,
  • Masahiko Ando,
  • Ryohei Yamamoto,
  • Shinichi Akiyama,
  • Sawako Kato,
  • Takayuki Katsuno,
  • Tomoki Kosugi,
  • Waichi Sato,
  • Naotake Tsuboi,
  • Yoshinari Yasuda,
  • Masashi Mizuno,
  • Yasuhiko Ito,
  • Seiichi Matsuo,
  • Shoichi Maruyama

DOI
https://doi.org/10.1371/journal.pone.0100835
Journal volume & issue
Vol. 9, no. 6
p. e100835

Abstract

Read online

BACKGROUND: Multiple studies have shown cigarette smoking to be a risk factor for chronic kidney disease. However, it is unknown whether smoking similarly increases the risk for progression of membranous nephropathy. METHODS: This study used the Nagoya Nephrotic Syndrome Cohort Study (N-NSCS), including 171 patients with idiopathic membranous nephropathy (IMN) from 10 nephrology centers in Japan. The dose-response relationships between cigarette smoking and the outcomes were assessed by using multivariate Cox proportional hazards models adjusted for clinically relevant factors. The primary outcome was a 30% decline in the estimated glomerular filtration rate (eGFR). The secondary outcome was first complete remission (CR) of proteinuria. RESULTS: During the observation period (median, 37 months; interquartile range, 16-71 months), 37 (21.6%) patients developed a 30% decline in eGFR and 2 (1.2%) progressed to ESRD. CR occurred in 103 (60.2%) patients. Multivariate Cox proportional hazards models revealed current smoking (adjusted hazard ratio [HR], 7.81 [95% confidence interval (CI), 3.17-19.7]), female sex (adjusted HR, 3.58 [95% CI, 1.87-8.00]), older age (adjusted HR, 1.71 [95% CI, 1.13-2.62] per 10 years), the number of cigarettes smoked daily (adjusted HR, 1.61 [95% CI, 1.23-2.09] per 10 cigarettes daily), and cumulative smoking of ≥40 pack-years (adjusted HR, 5.56 [95% CI, 2.17-14.6]) to be associated with a 30% decline in eGFR. However, smoking was not associated with CR. CONCLUSION: Smoking is a significant and dose-dependent risk factor for IMN progression. All patients with IMN who smoke should be encouraged to quit.